Iktos
Yann Gaston-Mathe has extensive work experience in various roles within the pharmaceutical and biotechnology industries. Yann is the Co-founder and CEO of Iktos since October 2016. Prior to that, they worked at IntegraGen as the Acting Head of R&D from March 2018 to October 2018, and as the VP of Molecular Diagnostics from February 2017 to February 2018. Yann was a Partner at Quinten from July 2015 to August 2017, where they provided data science services for the life science and healthcare industries. Yann also served as a Senior Manager at CEPTON Strategies from February 2016 to March 2017. Yann has experience at Optivia Biotechnology, where they worked as the Acting European Head of Business and Corporate Development from September 2014 to March 2016. Yann served as the Director of Life Sciences and Healthcare at Hypercube Research, a Data Analytics company, from June 2012 to June 2014. Additionally, Yann had various roles at Ipsen, including Project Director of R&D and TechOps Transformation from April 2011 to June 2012, Senior Director of Research Strategic Planning from April 2009 to September 2011, and Director of IS/IT Governance from March 2006 to April 2009. Yann began their career at Servier as the Head of IS Coordination for R&D from 1995 to 2001. Throughout their career, Yann has been involved in business and commercial development, research strategy, portfolio management, and data analytics in the healthcare industry.
Yann Gaston-Mathe completed their MS degree in Maths, Physics, Chemistry, and Biology at École Polytechnique from 1990 to 1993. Following that, they pursued another MS degree in Biology, Genetics, and Biochemistry from Institut national agronomique Paris-Grignon between 1993 and 1995.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.